https://www.selleckchem.com/pr....oducts/ly3039478.htm
There were also no significant differences in moderate to severe exacerbation, COPD-related mortality, or cardiovascular disease-related mortality among ICS/LAMA/LABA combinations, and the risk of major adverse cardiovascular events was not different. A significantly lower risk of pneumonia was found in fluticasone propionate (FP)/glycopyrrolate/salmeterol (SAL) than FP/tiotropium/SAL median odds ratio [OR] (95% credible interval [CrI]) = 0 [0-0.72] and FP/umeclidinium/SAL median OR (95% Crl) = 0 [0-0.97]. There were no significant di
Beğen
Yorum Yap
Paylaş
